Views | |
---|---|
Safety and tolerability of the combination therapy with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in patients with chronic hepatitis C in Poland : interim analysis of data from EAP program | 39 |
czerwca 2023 | lipca 2023 | sierpnia 2023 | września 2023 | października 2023 | listopada 2023 | grudnia 2023 | |
---|---|---|---|---|---|---|---|
Safety and tolerability of the combination therapy with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in patients with chronic hepatitis C in Poland : interim analysis of data from EAP program | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
Views | |
---|---|
ciesla_janas-skulina_mach_zejc-bajsarowicz_et-al_safety_and_tolerability_of_the_combination_2004.pdf | 18 |
ciesla_janas-skulina_mach_zejc-bajsarowicz_et-al_safety_and_tolerability_of_the_combination_2004.odt | 7 |
Views | |
---|---|
United States | 16 |
Germany | 3 |
Poland | 3 |
Sweden | 3 |
Vietnam | 3 |
Bulgaria | 1 |
France | 1 |
Ireland | 1 |
Netherlands | 1 |
Views | |
---|---|
Chandler | 7 |
Ashburn | 3 |
Hanoi | 3 |
Des Moines | 2 |
Burgas | 1 |
Domaszowice | 1 |
Dublin | 1 |
Groningen | 1 |
Hanover | 1 |
Krakow | 1 |